Effects of dapagliflozin on postprandial lipid metabolism in type 2 diabetes mellitus

Benjamin Burggraaf, Nadine M.C. Pouw, Salvador Fernández Arroyo, Leonie C. van Vark-van der Zee, Gert Jan M. van de Geijn, Erwin Birnie, Jeannine Huisbrink, Ellen M. van der Zwan, Wouter W. de Herder, Monique T. Mulder, Patrick C.N. Rensen, Manuel Castro Cabezas

OnderzoeksoutputAcademicpeer review

26 Downloads (Pure)

Samenvatting

Objectives: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) modulate lipid metabolism and improve cardiovascular morbidity and mortality in patients with type 2 diabetes mellitus (T2DM). The exact cardioprotective mechanism of SGLT2i is unclear. We evaluated the effects of SGLT2i on postprandial lipids, lipoprotein concentrations, glucose and fatty acids.

Design: A placebo-controlled randomized, proof-of-concept study.

Methods: Fourteen male patients with T2DM on intensive insulin regimen were randomly and double-blind allocated to 12 weeks dapagliflozin (10 mg) or placebo. Postprandial effects were assessed with an 8-h standardized oral fat loading test.

Results: Mean glycated A1c did not change by dapagliflozin, but the mean daily insulin dose was significantly reduced. Although dapagliflozin did not affect fasting or postprandial levels of glucose and insulin, it increased the postprandial levels of glucagon. While fasting levels of free fatty acids and beta-hydroxybutyrate (bHBA) were unchanged, dapagliflozin significantly increased the postprandial bHBA response. This was seen in the context of increased postprandial glucagon levels by dapagliflozin, without influencing postprandial insulin or glucose levels. Dapagliflozin did not affect fasting or postprandial plasma cholesterol and triglycerides nor postprandial inflammatory markers. Fasting apolipoprotein B48 was decreased without affecting the postprandial response. Markers of inflammation and vascular function did not change.

Conclusion: Treatment with dapagliflozin of patients with T2DM led to a reduction of fasting chylomicron remnants and increased postprandial ketone bodies compared to placebo suggesting enhanced hepatic fatty acid oxidation. The latter may have been caused by decreasing the insulin-glucagon ratio. The beneficial clinical effects seen in the trials using dapagliflozin most likely are not due to effects on postprandial inflammation nor postprandial lipemia.

Originele taal-2English
Pagina's (van-tot)597-605
Aantal pagina's9
TijdschriftEuropean Journal of Endocrinology
Volume186
Nummer van het tijdschrift5
DOI's
StatusPublished - 6-apr.-2022

Citeer dit